Abstract
We thank Wang et al1 for their interest and suggestions on our study on melanoma differentiation–associated gene 5-related interstitial lung disease (MDA5-ILD), which highlighted that tofacitinib (TOF) use might have a potential effect on improving the outcomes of MDA5-ILD.2 We completely agree with their valuable suggestions.